DexCom (NASDAQ:DXCM) Upgraded by StockNews.com to Buy

DexCom (NASDAQ:DXCM) was upgraded by research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Friday.

A number of other research analysts have also weighed in on the company. BTIG Research reduced their price objective on DexCom from $156.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, July 26th. Baird R W lowered DexCom from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 26th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $145.00 price objective on shares of DexCom in a research report on Tuesday, July 23rd. Sanford C. Bernstein raised their price objective on DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research report on Friday. Finally, Piper Sandler reiterated an “overweight” rating and set a $90.00 target price on shares of DexCom in a research note on Monday, August 26th. Six investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, DexCom has an average rating of “Moderate Buy” and an average price target of $104.59.

DexCom Stock Down 1.9 %

Shares of NASDAQ:DXCM traded down $1.41 during trading on Friday, hitting $73.44. The stock had a trading volume of 14,560,038 shares, compared to its average volume of 3,904,948. DexCom has a 12 month low of $62.34 and a 12 month high of $142.00. The company has a market capitalization of $29.21 billion, a PE ratio of 47.38, a PEG ratio of 2.16 and a beta of 1.18. The firm’s fifty day moving average is $70.11 and its 200 day moving average is $98.24. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, October 24th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.02. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The firm had revenue of $994.20 million during the quarter, compared to analyst estimates of $991.55 million. Analysts anticipate that DexCom will post 1.69 EPS for the current fiscal year.

Insider Transactions at DexCom

In other news, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the transaction, the executive vice president now directly owns 75,451 shares in the company, valued at $5,217,436.65. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. In related news, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the transaction, the executive vice president now directly owns 75,451 shares in the company, valued at approximately $5,217,436.65. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Michael Jon Brown sold 652 shares of DexCom stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total value of $45,346.60. Following the transaction, the executive vice president now owns 66,249 shares in the company, valued at $4,607,617.95. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,824 shares of company stock worth $126,390 in the last ninety days. Insiders own 0.30% of the company’s stock.

Hedge Funds Weigh In On DexCom

Institutional investors and hedge funds have recently bought and sold shares of the stock. Taylor Frigon Capital Management LLC lifted its position in DexCom by 51.6% during the third quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company’s stock valued at $2,182,000 after purchasing an additional 11,075 shares in the last quarter. Waters Parkerson & CO. LLC lifted its position in shares of DexCom by 4.2% in the second quarter. Waters Parkerson & CO. LLC now owns 272,641 shares of the medical device company’s stock valued at $30,912,000 after acquiring an additional 10,892 shares in the last quarter. Legal & General Group Plc boosted its stake in shares of DexCom by 1.7% in the second quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company’s stock worth $339,352,000 after acquiring an additional 49,076 shares during the period. Factory Mutual Insurance Co. boosted its stake in shares of DexCom by 136.1% in the third quarter. Factory Mutual Insurance Co. now owns 404,230 shares of the medical device company’s stock worth $27,100,000 after acquiring an additional 233,000 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund grew its position in shares of DexCom by 533.1% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 36,510 shares of the medical device company’s stock worth $4,140,000 after purchasing an additional 30,743 shares in the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.